SINTX forecasts Q3 revenue between $900,000 and $1.1 million
Biotech firm SINTX Technologies provides preliminary Q3 revenue guidance, signaling a sequential decline from prior quarters.
SINTX Technologies on Monday forecasted third-quarter revenue of $900,000 to $1.1 million, reflecting a sequential decrease from the prior quarter.
The company, which develops silicon nitride-based biomedical products, did not disclose net income or other financial metrics in its preliminary outlook. The guidance follows a second-quarter revenue of $1.4 million reported in August, indicating a projected decline of roughly 21% to 36% quarter-on-quarter.
SINTX attributed the revenue projection to ongoing operational adjustments and market conditions affecting its product commercialization. The firm has not provided a formal earnings release or conference call schedule for the quarter.
Analysts tracking the company’s performance noted that the guidance suggests continued challenges in scaling production and achieving broader market adoption. SINTX shares, listed on the OTC Markets under the ticker SINT, have traded in a narrow range in recent months, reflecting limited liquidity and investor interest.
The company did not specify whether the forecast includes any potential contributions from new partnerships or product launches scheduled for the quarter.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →